Donanemab
Donanemab
Donanemab (pronounced doh-nuh-nem-ab) is a monoclonal antibody designed for the treatment of Alzheimer's disease. It is developed by Eli Lilly and Company, a multinational pharmaceutical company.
Etymology
The name "Donanemab" is derived from the generic naming system for therapeutic monoclonal antibodies, where "-mab" stands for monoclonal antibody. The prefix "Dona-" does not have a specific meaning in this context.
Mechanism of Action
Donanemab works by targeting a modified form of beta-amyloid, known as N3pG. This form of beta-amyloid is a key component of the plaques found in the brains of Alzheimer's patients. By binding to these plaques, Donanemab helps to clear them from the brain, potentially slowing the progression of the disease.
Clinical Trials
Donanemab has undergone Phase 2 clinical trials, known as the TRAILBLAZER-ALZ study. The results of this trial showed that Donanemab significantly slowed the decline in cognition and daily function in patients with early symptomatic Alzheimer's disease.
Related Terms
External links
- Medical encyclopedia article on Donanemab
- Wikipedia's article - Donanemab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski